Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Stopped Abandoned prior to launch.
Conditions
- Stage III Breast Cancer
- Stage IV Breast Cancer
- Stage III Lung Cancer
- Stage IV Lung Cancer
- AML
- Multiple Myeloma in Relapse
- Carcinoma
- Carcinoma, Pancreatic
- Carcinoma of Lung
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Carcinoma Prostate
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Small Cell Lung
- Carcinoma, Ovarian
- Carcinoma Bladder
- Carcinoma of Esophagus
- Carcinoma Cervix
- Carcinoma, Thymic
- Carcinoma, Ductal
- Carcinoma of the Head and Neck
- Carcinoma of the Lip
- Carcinoma of the Oral Cavity
- Carcinoma of Unknown Primary
- Carcinoma of the Skin
- Carcinoma of the Anus
- Carcinoma of the Larynx
- Carcinoma of the Penis
- Carcinoma of the Oropharynx
- Carcinoma of the Appendix
- Carcinoma of the Paranasal Sinus
- Carcinoma of the Vulva
- Malignant Pleural Effusion
- Malignant Ascites
- Mesothelioma
- Cholangiocarcinoma
Sponsor
Travera Inc